The i.p. dose of paclitaxel (15 mg/kg) used in this study was determined after a series of pilot experiments which indicated that it produced significant resistance in HEK293/ABCC10 tumor-xenograft model compared to the HEK293/pcDNA3.1 tumor-xenograft model. Here, ABCC10 is linked to neoplasm.